CN115300459A - 纳米酶复合水凝胶滴眼液的制备方法 - Google Patents
纳米酶复合水凝胶滴眼液的制备方法 Download PDFInfo
- Publication number
- CN115300459A CN115300459A CN202210964063.3A CN202210964063A CN115300459A CN 115300459 A CN115300459 A CN 115300459A CN 202210964063 A CN202210964063 A CN 202210964063A CN 115300459 A CN115300459 A CN 115300459A
- Authority
- CN
- China
- Prior art keywords
- solution
- preparation
- aqueous solution
- eye drops
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 29
- 229940012356 eye drops Drugs 0.000 title claims abstract description 25
- 239000002131 composite material Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000017 hydrogel Substances 0.000 title claims abstract description 13
- 108010010803 Gelatin Proteins 0.000 claims abstract description 14
- 239000008273 gelatin Substances 0.000 claims abstract description 14
- 229920000159 gelatin Polymers 0.000 claims abstract description 14
- 235000019322 gelatine Nutrition 0.000 claims abstract description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 8
- SQWDWSANCUIJGW-UHFFFAOYSA-N cobalt silver Chemical compound [Co].[Ag] SQWDWSANCUIJGW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002105 nanoparticle Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 12
- 239000001263 FEMA 3042 Substances 0.000 claims description 12
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 12
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 12
- 229940033123 tannic acid Drugs 0.000 claims description 12
- 235000015523 tannic acid Nutrition 0.000 claims description 12
- 229920002258 tannic acid Polymers 0.000 claims description 12
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 11
- 238000009210 therapy by ultrasound Methods 0.000 claims description 11
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 244000028419 Styrax benzoin Species 0.000 claims description 4
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 4
- 235000008411 Sumatra benzointree Nutrition 0.000 claims description 4
- 229960002130 benzoin Drugs 0.000 claims description 4
- 235000019382 gum benzoic Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940071536 silver acetate Drugs 0.000 claims description 4
- 238000001354 calcination Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- QPXZALHPZYRQIT-UHFFFAOYSA-N ethanol;methoxymethane Chemical compound CCO.COC QPXZALHPZYRQIT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- PLKATZNSTYDYJW-UHFFFAOYSA-N azane silver Chemical compound N.[Ag] PLKATZNSTYDYJW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000003999 initiator Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 9
- 206010023332 keratitis Diseases 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 abstract description 6
- 206010061788 Corneal infection Diseases 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 230000001678 irradiating effect Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 16
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 4
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000033856 Chemical eye injury Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical group N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于滴眼液药物领域，针对引起角膜炎的病原体对常见眼部抗生素的耐药性呈现增加趋势，亟需新型抗菌药物的问题，本发明提供一种纳米酶复合水凝胶滴眼液的制备方法，先利用六水氯化钴与氨水的配位反应以及硝酸银与单宁酸的氧化还原反应合成一种单宁酸配合的银钴复合纳米粒子；将银钴复合纳米粒子和丙烯酸酯修饰明胶混合并超声溶解，然后通过紫外光照射制备出纳米酶复合水凝胶滴眼液。本发明制备方法操作简便且制备时间短；所得滴眼液对多种细菌和真菌显示了广谱杀菌的效果，并对细菌性和耐药菌角膜感染具有良好的预防治疗效果。
Description
技术领域
本发明属于滴眼液药物领域，具体涉及纳米酶复合水凝胶滴眼液的制备方法。
背景技术
细菌性角膜炎是由于细菌侵袭角膜引发的感染，发病迅速，严重者会引发角膜溃疡甚至穿孔，是发展中国家主要致盲性眼病之一。最常见的诱发因素包括：使用隐形眼镜，特别是夜间或长期佩戴隐形眼镜以及镜片消毒不充分；外伤；眼部手术特别是角膜手术；慢性眼表疾病；全身性疾病如糖尿病和/或外用皮质类固醇的长期使用。在常见细菌性病原体中，引起角膜炎最常见的病原体包括金黄色葡萄球菌、铜绿假单胞菌、肺炎链球菌和沙雷氏菌，其中以铜绿假单胞菌性角膜炎感染发病最为严重并且难以治疗。临床上对铜绿假单胞菌性角膜炎的治疗以病灶清除和局部抗生素的频繁用药为主，以尽可能高效快速的控制住角膜溃疡发展。但是，抗生素的使用亦存在一定程度的风险和问题。一项对外用抗生素治疗细菌性角膜炎的临床实验回顾分析显示，与氟喹诺酮类药物相比，氨基糖苷类头孢菌素类药物引起眼部不适或化学结膜炎等轻微不良事件的相对风险有所增加。对眼表分离铜绿假单胞菌耐药性回顾分析表明，铜绿假单胞菌对环丙沙星(9％)、庆大霉素(22％)和头孢他啶(13％)等常见眼部抗生素的平均耐药率虽然相对较低，但对于其耐药性有逐年升高的趋势。所以，对于研发针对铜绿假单胞菌性角膜炎治疗的新型抗菌药物仍是紧迫且必需的。
发明内容
针对引起角膜炎的病原体对常见眼部抗生素的耐药性呈现增加趋势，亟需新型抗菌药物的上述问题，本发明提供一种纳米酶复合水凝胶滴眼液的制备方法，先利用六水氯化钴与氨水的配位反应以及硝酸银与单宁酸的氧化还原反应合成一种单宁酸配合的银钴复合纳米粒子(TCN)；以水为媒介，将TCN和丙烯酸酯修饰明胶混合并超声至均匀，然后通过紫外光照射一步制备出纳米酶复合水凝胶材料(TCNH)；进而与过氧化氢溶液混合均匀即得TCNH滴眼液。所得滴眼液对多种细菌及真菌显示了广谱杀菌的效果，并对细菌性和耐药菌角膜感染具有良好的预防治疗效果。
本发明提供的纳米酶复合水凝胶滴眼液的制备方法包括以下步骤：
纳米酶复合水凝胶滴眼液的制备方法，包括以下步骤：
(1)向氯化钴水溶液中滴加少量氨水，反应一段时间，再滴加氯化钴水溶液继续反应；
(2)将醋酸银加入到氨水溶液中并完全溶解，将该溶液缓慢滴加到步骤(1)中，搅拌一段时间后滴加单宁酸溶液，继续搅拌，析出沉淀；离心、清洗、干燥沉淀并于350-450℃下煅烧1-4h，即得单宁酸配合的银钴复合纳米粒子；
(3)将制得的单宁酸配合的银钴复合纳米粒子加入到5wt％-7.5wt％的丙烯酸酯修饰明胶的水溶液中，并加入安息香二甲醚乙醇溶液作为引发剂，超声至均匀，然后将上述混合物置于紫外光下照射，形成凝胶状溶液，再加入过氧化氢溶液并在室温下超声至均匀，即得纳米酶复合水凝胶滴眼液。
进一步的，所述氯化钴水溶液的浓度为20-30mmol/L。
进一步的，所述氨水为含氨20～28％的水溶液。
进一步的，所述步骤(1)向氯化钴水溶液中滴加氨水，逐步升温至55-65℃，并继续搅拌12-18min；再滴加氯化钴水溶液继续反应1-4h。
进一步的，所述步骤(2)缓慢滴加银氨溶液，搅拌15min，缓慢滴加单宁酸溶液，室温搅拌16h。
进一步的，所述步骤(2)依次用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h。
进一步的，所述丙烯酸酯修饰明胶为甲基丙烯酸酯化明胶。
进一步的，所述步骤(3)混合物中，丙烯酸酯修饰明胶的质量浓度为2.0％-6.0％。
进一步的，所述步骤(3)紫外光下照射时间为12-18min。
进一步的，所述步骤(3)混合物中，丙烯酸酯修饰明胶与单宁酸配合的银钴复合纳米粒子的质量比为8-12：1。
本发明的有益效果：制备方法操作简便且制备时间短；所得滴眼液对多种细菌和真菌显示了广谱杀菌的效果，并对细菌性和耐药菌角膜感染具有良好的预防治疗效果。
附图说明
图1为实施例制备的TCN纳米酶的扫描电镜照片；纳米酶为球状堆积形貌。
图2为实施例制备的TCNH滴眼液的扫描电镜照片；滴眼液形貌为典型的水凝胶数十微米大孔的形貌。
图3为实施例制备的TCNH滴眼液的光学照片；纳米酶均匀分散在滴眼液中。
图4为实施例制备的TCNH滴眼液的体外抑菌实验-平板实验。
图5为实施例制备的TCNH滴眼液的体外抑菌实验-对照组和H2O2组被染成绿色的活细菌数数量。
图6为实施例制备的TCNH滴眼液的体外抑菌实验-扫描电镜下对照组和H2O2组细菌形态。
图7为实施例制备的TCNH滴眼液的体内抑菌实验(铜绿假单胞菌)-对照组和H2O2组角膜明显感染情况。
图8为实施例制备的TCNH滴眼液的体内抑菌实验(铜绿假单胞菌耐药菌)。
具体实施方式
下面结合具体实施例对本发明做进一步详细说明。
实施例
(1)向离心管中加入238.0mg六水氯化钴；
(2)向步骤(1)的离心管中加入50.0mL水并超声至完全溶解；
(3)向步骤(2)的离心管中逐滴加入1.0mL 25％氨水溶液，逐步升温至60℃，并继续搅拌15min；
(4)向步骤(3)的离心管中加入20.0mL25 mmol/L六水氯化钴溶液，继续反应3h；
(5)250.3mg醋酸银加入到10mL 25％氨水溶液中，超声至完全溶解；
(6)将步骤(5)中溶液缓慢滴加到步骤(4)的溶液中，并继续搅拌15min；
(7)2.34g单宁酸加入到40.0mL水中，超声至完全溶解；
(8)将步骤(7)中溶液缓慢滴加到步骤(6)的溶液中，室温搅拌16h；
(9)将步骤(8)中溶液离心，并用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h，即得TCN；
(10)向离心管中加入7.5wt％150mg丙烯酸酯修饰的明胶；
(11)向步骤(10)的离心管中加入3.0mL水并超声至完全溶解；
(12)向离心管中加入15.0mg TCN、及2μL的浓度10wt％安息香二甲醚乙醇溶液，并超声至均匀；
(13)将步骤(12)的离心管置于紫外光下照射15min，安息香二甲醚作为光引发剂，丙烯酸酯修饰的明胶浓度较低，因此发生轻微交联，形成凝胶状水溶液，TCN均匀分散在凝胶水溶液中；
(14)向步骤(13)的离心管中加入过氧化氢溶液并在室温下超声至均匀即得TCNH滴眼液。
抑菌实验
将所得实施例制备的TCNH滴眼液应用于体外大肠杆菌、铜绿假单胞菌、耐药性铜绿假单胞菌和白色念珠菌评价以及体内铜绿假单胞菌和耐药铜绿假单胞菌角膜感染的预防治疗实验。
图4-图6为TCNH滴眼液的体外抑菌实验结果。铜绿假单胞菌、耐药铜绿假单胞菌、大肠杆菌和白色念珠菌的抑菌效果：如图4所示，对照组和H2O2组细菌长满了平板，TCNH和TCNH+H2O2组平板无细菌菌落生成。如图5所示，对照组和H2O2组被染成绿色的活细菌数目较多，被染成红色的死细菌很少，TCNH和TCNH+H2O2组细菌个数显著减少，视野里只有零星几个。如图6所示，扫描电镜下对照组和H2O2组细菌形态规则完好，TCNH和TCNH+H2O2组细菌形貌变得不规则，有明显皱缩甚至凹陷。
TCNH滴眼液的体内抑菌实验(铜绿假单胞菌)，结果如图7所示，对照组和H2O2组角膜明显感染，TCNH组有轻微感染，TCNH+H2O2组无感染，角膜中细菌数量统计表明TCNH组细菌数量级显著降低。
TCNH滴眼液的体内抑菌实验(铜绿假单胞菌耐药菌)，结果如图8所示，对照组、庆大霉素组(Gen)和妥布霉素组(Tob)均有明显感染，TCNH+H2O2组无感染，角膜中细菌数量统计表明，TCNH组耐药细菌数量级显著降低。
以上所述的实施例仅是对本发明的优选实施方式进行描述，并非对本发明的范围进行限定，在不脱离本发明设计精神的前提下，本领域普通技术人员对本发明的技术方案作出的各种变形和改进，均应落入本发明权利要求书确定的保护范围内。
Claims (10)
1.纳米酶复合水凝胶滴眼液的制备方法，其特征在于，包括以下步骤：
(1)向氯化钴水溶液中滴加少量氨水，反应一段时间，再滴加氯化钴水溶液继续反应；
(2)将醋酸银加入到氨水溶液中并完全溶解，将该溶液缓慢滴加到步骤(1)中，搅拌一段时间后滴加单宁酸溶液，继续搅拌，析出沉淀；离心、清洗、干燥沉淀并于350-450℃下煅烧1-4h，即得单宁酸配合的银钴复合纳米粒子；
(3)将制得的单宁酸配合的银钴复合纳米粒子加入到5wt％-7.5wt％的丙烯酸酯修饰明胶的水溶液中，并加入安息香二甲醚乙醇溶液作为引发剂，超声至均匀，然后将上述混合物置于紫外光下照射，形成凝胶状水溶液，再加入过氧化氢溶液并在室温下超声至均匀，即得纳米酶复合水凝胶滴眼液。
2.根据权利要求1所述的制备方法，其特征在于，所述氯化钴水溶液的浓度为20-30mmol/L。
3.根据权利要求1所述的制备方法，其特征在于，所述氨水为含氨20～28％的水溶液。
4.根据权利要求1所述的制备方法，其特征在于，所述步骤(1)向氯化钴水溶液中滴加氨水，逐步升温至55-65℃，并继续搅拌12-18min；再滴加氯化钴水溶液继续反应1-4h。
5.根据权利要求1所述的制备方法，其特征在于，所述步骤(2)缓慢滴加银氨溶液，搅拌15min，缓慢滴加单宁酸溶液，室温搅拌16h。
6.根据权利要求1所述的制备方法，其特征在于，所述步骤(2)依次用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h。
7.根据权利要求1所述的制备方法，其特征在于，所述丙烯酸酯修饰明胶为甲基丙烯酸酯化明胶。
8.根据权利要求1所述的制备方法，其特征在于，所述步骤(3)混合物中，丙烯酸酯修饰明胶的质量浓度为2.0％-6.0％。
9.根据权利要求1所述的制备方法，其特征在于，所述步骤(3)紫外光下照射时间为12-18min。
10.根据权利要求1或2所述的制备方法，其特征在于：所述步骤(3)混合物中，丙烯酸酯修饰明胶与单宁酸配合的银钴复合纳米粒子的质量比为(8-12)：1。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210964063.3A CN115300459B (zh) | 2022-08-11 | 2022-08-11 | 纳米酶复合水凝胶滴眼液的制备方法 |
| PCT/CN2023/076110 WO2024031949A1 (zh) | 2022-08-11 | 2023-02-15 | 纳米酶复合水凝胶滴眼液的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210964063.3A CN115300459B (zh) | 2022-08-11 | 2022-08-11 | 纳米酶复合水凝胶滴眼液的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115300459A true CN115300459A (zh) | 2022-11-08 |
| CN115300459B CN115300459B (zh) | 2023-07-18 |
Family
ID=83862902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210964063.3A Active CN115300459B (zh) | 2022-08-11 | 2022-08-11 | 纳米酶复合水凝胶滴眼液的制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115300459B (zh) |
| WO (1) | WO2024031949A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024031949A1 (zh) * | 2022-08-11 | 2024-02-15 | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | 纳米酶复合水凝胶滴眼液的制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100143183A1 (en) * | 2006-12-20 | 2010-06-10 | Servicios Industriales Peñoles, S.A. De C.V. | Process for manufacture of nanometric, monodisperse, stable metallic silver and a product obtained therefrom |
| US20130177504A1 (en) * | 2011-06-17 | 2013-07-11 | Annuary Healthcare, Inc. | Nanoscale Particle Formulations and Methods |
| CN111363072A (zh) * | 2020-03-06 | 2020-07-03 | 西南交通大学 | 一种基于具有等离子效应的多酚-银纳米酶的水凝胶制备方法 |
| US20200254142A1 (en) * | 2019-02-08 | 2020-08-13 | University Of New Hampshire | Injectable porous hydrogels |
| CN113248730A (zh) * | 2021-04-22 | 2021-08-13 | 上海健康医学院 | 聚丙烯酰胺-纳米纤维素晶-银纳米颗粒复合导电抗冻有机水凝胶及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3081919B2 (ja) * | 1999-08-16 | 2000-08-28 | 農林水産省蚕糸・昆虫農業技術研究所長 | 抗菌性高分子素材及びその製造方法 |
| US8361188B2 (en) * | 2009-04-03 | 2013-01-29 | Indian Institute Of Science | Methods for preparing metal and metal oxide nanoparticles |
| CN114129766B (zh) * | 2021-12-13 | 2023-03-24 | 昆明理工大学 | 一种纳米酶抗菌水凝胶的制备方法及其应用 |
| CN115300459B (zh) * | 2022-08-11 | 2023-07-18 | 山东第一医科大学附属眼科研究所(山东省眼科研究所山东第一医科大学附属青岛眼科医院) | 纳米酶复合水凝胶滴眼液的制备方法 |
-
2022
- 2022-08-11 CN CN202210964063.3A patent/CN115300459B/zh active Active
-
2023
- 2023-02-15 WO PCT/CN2023/076110 patent/WO2024031949A1/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100143183A1 (en) * | 2006-12-20 | 2010-06-10 | Servicios Industriales Peñoles, S.A. De C.V. | Process for manufacture of nanometric, monodisperse, stable metallic silver and a product obtained therefrom |
| US20130177504A1 (en) * | 2011-06-17 | 2013-07-11 | Annuary Healthcare, Inc. | Nanoscale Particle Formulations and Methods |
| US20200254142A1 (en) * | 2019-02-08 | 2020-08-13 | University Of New Hampshire | Injectable porous hydrogels |
| CN111363072A (zh) * | 2020-03-06 | 2020-07-03 | 西南交通大学 | 一种基于具有等离子效应的多酚-银纳米酶的水凝胶制备方法 |
| CN113248730A (zh) * | 2021-04-22 | 2021-08-13 | 上海健康医学院 | 聚丙烯酰胺-纳米纤维素晶-银纳米颗粒复合导电抗冻有机水凝胶及其制备方法和应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024031949A1 (zh) * | 2022-08-11 | 2024-02-15 | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | 纳米酶复合水凝胶滴眼液的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024031949A1 (zh) | 2024-02-15 |
| CN115300459B (zh) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090068089A1 (en) | Novel method of manufacture of silver oxide nano particles | |
| Nandhini et al. | Recent advances in green synthesized nanoparticles for bactericidal and wound healing applications | |
| CN104857551B (zh) | 一种含银抗菌敷料及制备方法 | |
| Karthikeyan et al. | Biocidal and biocompatible hybrid nanomaterials from biomolecule chitosan, alginate and ZnO | |
| CN115300459A (zh) | 纳米酶复合水凝胶滴眼液的制备方法 | |
| US20220287961A1 (en) | Compositions and methods for treatment of ocular diseases | |
| Guo et al. | Reversible antibiotic loading and pH-responsive release from polymer brushes on contact lenses for therapy and prevention of corneal infections | |
| US20120189534A1 (en) | Method of manufacture of silver oxide nano particles | |
| HU225329B1 (en) | Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity | |
| JP5337928B2 (ja) | 銀／水、銀ゲル、および銀ベースの組成物、並びにこれらの製造方法および使用方法 | |
| WO2019135136A1 (en) | Coordination complexes having microbial activity and incorporable in hyaluronic acid compositions | |
| CN113041348B (zh) | 具有一氧化氮/光动力协同抗菌、抗炎作用的纳米复合体系及其制备方法与应用 | |
| Li et al. | AgNPs-loaded chitosan/sodium alginate hydrogel film by in-situ green reduction with tannins for enhancing antibacterial activity | |
| CN109675084A (zh) | 抗菌敷料及其制备方法和应用 | |
| CN1369206A (zh) | 钠米银消毒凝胶及其制备方法和应用 | |
| CN115304053B (zh) | 碳纳米点、可注射碳纳米点-ε-聚赖氨酸水凝胶及其制备方法与应用 | |
| CN111803695A (zh) | 一种基于银掺杂碳点的no释放型伤口敷料的制备方法及其产品和应用 | |
| EP2170081A1 (en) | Antimicrobial compositions | |
| CA2463256C (en) | Silver salts of sucrose-octasulphate | |
| EP1121929B1 (en) | Composition comprising di- and trisodiumsalts of echinochrome for treating ocular conditions | |
| CN114748450B (zh) | 一种近红外响应Bi/BiOCl异质结复合纤维蛋白凝胶及其制备与应用 | |
| Shao et al. | A facile method to construct ZIF-8 MOFs on contact lens for high antibiotics loading and self-defensive release | |
| RU2682711C1 (ru) | Антисептическое средство | |
| CN115094039B (zh) | 一种维甲酸-钙纳米缓释剂及其在促进干细胞向神经元分化中的应用 | |
| CN115400212B (zh) | 有机室温磷光纳米颗粒及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |